ADMP Snubbed Again, OCUL, DNAI Skid On Trial Data, AGN Gets FDA Nod. SRPT Abuzz

Shares of Sarepta Therapeutics Inc. (SRPT) were up more than 25% in after hours on Monday after the FDA request for dystrophin data from biopsies already obtained from an ongoing confirmatory study reignited hopes that the company's Duchenne Muscular Dystrophy drug candidate Eteplirsen stand a chance of getting approved.

from RTT - Biotech http://ift.tt/1PCKZAZ
via IFTTT